Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PMD
CUSIPN/A
Phone978-206-8220
Debt
Debt-to-Equity Ratio0.11
Current Ratio2.83
Quick Ratio2.83
Price-To-Earnings
Trailing P/E Ratio23.55
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$39.70 million
Price / Sales2.78
Cash Flow$1.4144 per share
Price / Cash14.14
Book Value$3.39 per share
Price / Book5.90
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$6.12 million
Net Margins14.79%
Return on Equity27.53%
Return on Assets19.01%
Miscellaneous
Employees231
Outstanding Shares5,510,000
Market Cap$118.02 million
Psychemedics (NASDAQ:PMD) Frequently Asked Questions
What is Psychemedics' stock symbol?
Psychemedics trades on the NASDAQ under the ticker symbol "PMD."
How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?
Psychemedics announced a quarterly dividend on Tuesday, July 24th. Shareholders of record on Tuesday, August 7th will be paid a dividend of $0.18 per share on Friday, August 17th. This represents a $0.72 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date is Monday, August 6th. View Psychemedics' Dividend History.
How were Psychemedics' earnings last quarter?
Psychemedics Corp. (NASDAQ:PMD) posted its quarterly earnings results on Tuesday, July, 24th. The company reported $0.21 EPS for the quarter. The firm earned $10.79 million during the quarter. Psychemedics had a net margin of 14.79% and a return on equity of 27.53%. View Psychemedics' Earnings History.
When is Psychemedics' next earnings date?
Who are some of Psychemedics' key competitors?
Who are Psychemedics' key executives?
Psychemedics' management team includes the folowing people:
- Mr. Raymond C. Kubacki Jr., Chairman, CEO & Pres (Age 73)
- Mr. Neil Lerner, VP of Fin. & Treasurer (Age 50)
- Mr. Michael I. Schaffer, VP of Laboratory Operations (Age 73)
- Dr. Werner A. Baumgartner Ph.D., Founder
- Ms. Annette Baumgartner, Founder
Has Psychemedics been receiving favorable news coverage?
Media headlines about PMD stock have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Psychemedics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news articles about the company an impact score of 48.09 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Psychemedics.
Who are Psychemedics' major shareholders?
Psychemedics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include North Star Investment Management Corp. (1.40%), Acadian Asset Management LLC (1.18%), Deprince Race & Zollo Inc. (1.07%), Quantum Capital Management (0.92%) and Mill Road Capital Management LLC (0.54%). Company insiders that own Psychemedics stock include Fred J Weinert, James V Dyke, Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr. View Institutional Ownership Trends for Psychemedics.
Which institutional investors are selling Psychemedics stock?
PMD stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, North Star Investment Management Corp. and Mill Road Capital Management LLC. Company insiders that have sold Psychemedics company stock in the last year include Michael I Schaffer and Neil Lerner. View Insider Buying and Selling for Psychemedics.
Which institutional investors are buying Psychemedics stock?
How do I buy shares of Psychemedics?
Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Psychemedics' stock price today?
One share of PMD stock can currently be purchased for approximately $20.00.
How big of a company is Psychemedics?
Psychemedics has a market capitalization of $118.02 million and generates $39.70 million in revenue each year. Psychemedics employs 231 workers across the globe.
How can I contact Psychemedics?
Psychemedics' mailing address is 289 GREAT ROAD, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.
MarketBeat Community Rating for Psychemedics (NASDAQ PMD)
MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote "Outperform" if you believe PMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
